Recent Research Analysts’ Ratings Updates for enGene (ENGN)

Several brokerages have updated their recommendations and price targets on shares of enGene (NASDAQ: ENGN) in the last few weeks:

• 11/12/2026 – enGene had its “outperform” rating reaffirmed by UBS Group.
• 11/12/2026 – enGene had its “outperform” rating reaffirmed by Raymond James Financial.
• 11/12/2026 – enGene was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $6.00 price target on the stock, up from $2.00.
• 11/12/2026 – enGene was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $4.00 price target on the stock.
• 10/30/2026 – enGene was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/16/2026 – enGene had its “buy” rating reaffirmed by HC Wainwright.
• 10/16/2026 – enGene was downgraded by Citigroup from “market perform” to “hold”.
• 10/15/2026 – enGene was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/13/2026 – enGene was upgraded by Jefferies Financial Group to “strong-buy”.

enGene Stock Performance

NASDAQ:ENGN traded up $0.47 during trading hours on Thursday, reaching $2.27. The company had a trading volume of 9,418,578 shares, compared to its average volume of 1,012,079. enGene Holdings Inc. has a 1-year low of $1.40 and a 1-year high of $12.25. The firm has a market cap of $152.47 million, a PE ratio of -1.10 and a beta of -0.24. The business’s 50 day moving average price is $1.77 and its 200-day moving average price is $4.06. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 10.21.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Research analysts forecast that enGene Holdings Inc. will post -1.82 EPS for the current year.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.